» Articles » PMID: 39525437

Secondary Amyloidosis Treated with Tocilizumab As a Complication of Temporal Arteritis

Overview
Specialty General Medicine
Date 2024 Nov 11
PMID 39525437
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Temporal arteritis is a large-vessel vasculitis mostly seen in the elderly. Amyloidosis may be secondary to a chronic inflammation of body organs. Here, we present the second case report of temporal arteritis complicated by amyloidosis that was successfully treated by tocilizumab.

Case Presentation: A 64-year-old female presented complaining of fatigue, fever, and diarrhea accompanied by abdominal pain. One year before presentation, she was diagnosed with temporal arteritis. She was treated with 15 mg/day oral prednisone for the last 6 months, with partial remission, but persistence of the fatigue and an elevated erythrocyte sedimentation rate (ESR, 56 mm/h). Physical examination showed tenderness of both temporal arteries and a soft abdomen. Colon tissue biopsy showed amyloid depositions in the vessels and stroma that were positive for Congo red staining. Tocilizumab was started with 8 mg/kg intravenous, the diarrhea resolved, and the arthralgia improved within 1 month, with a decrease in the ESR to 8 mm/h, and a C-reactive protein (CRP) level of 0.98 mg/dl. Monthly tocilizumab therapy remains efficacious 12 months later and was stopped due to lack of tocilizumab from the hospital. No side effects of tocilizumab were registered.

Conclusion: Chronic inflammation may be complicated by amyloidosis in patients with rheumatic diseases and genetic predisposition. Therefore, it is important to screen for intestinal Amyloid A (AA) amyloidosis in individuals with gastrointestinal disorders complicated by rheumatic disorders. AA amyloidosis may be complicated by temporal arteritis and presented with gastrointestinal symptoms such as diarrhea.

Learning Points: Amyloidosis is manifested by the deposition of insoluble protein aggregates in organs.Amyloid A (AA) amyloidosis occurs as a complication of chronic inflammation in patients with a genetic predisposition to rheumatic diseases.Temporal arteritis complicated with AA amyloidosis is extremely rare.

References
1.
Jung J, Kim Y, Kim J, Suh C, Kim H . Biologic therapy for amyloid A amyloidosis secondary to rheumatoid arthritis treated with interleukin 6 therapy: Case report and review of literature. Medicine (Baltimore). 2021; 100(32):e26843. PMC: 8360491. DOI: 10.1097/MD.0000000000026843. View

2.
Ponte C, Grayson P, Robson J, Suppiah R, Gribbons K, Judge A . 2022 American College of Rheumatology/EULAR Classification Criteria for Giant Cell Arteritis. Arthritis Rheumatol. 2022; 74(12):1881-1889. DOI: 10.1002/art.42325. View

3.
Tejederas M, Garcia F, Aguilera Morales W, de la Prada Alvarez F, Lazo M . Blockade of interleukin-6 as a possible therapeutic target for AA amyloidosis. Nefrologia (Engl Ed). 2021; . DOI: 10.1016/j.nefro.2021.01.006. View

4.
Hellmich B, Agueda A, Monti S, Luqmani R . Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future. Curr Rheumatol Rep. 2020; 22(12):84. PMC: 7549425. DOI: 10.1007/s11926-020-00964-x. View

5.
Okuda Y, Yamada T, Matsuura M, Takasugi K, Goto M . Ageing: a risk factor for amyloid A amyloidosis in rheumatoid arthritis. Amyloid. 2011; 18(3):108-11. DOI: 10.3109/13506129.2011.582198. View